Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:BCTX NASDAQ:BGXX NASDAQ:CSCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ABCTXBriacell Therap$0.80-4.0%$2.88$0.69▼$29.40$5.41M1.27748,170 shs1.55 million shsBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsCSCICOSCIENS Biopharma$4.33+5.6%$3.56$1.96▼$6.77$13.62M0.7611,119 shs10,314 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVARAVIVE0.00%0.00%0.00%0.00%0.00%BCTXBriacell Therap-3.98%-60.48%-74.41%-81.39%-94.22%BGXXBright Green0.00%0.00%0.00%0.00%-75.37%CSCICOSCIENS Biopharma+6.91%+25.73%+23.01%+47.33%+432,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAVARAVIVEN/AN/AN/AN/AN/AN/AN/AN/ABCTXBriacell Therap1.4582 of 5 stars3.52.00.00.00.60.00.6BGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/ACSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVARAVIVE 0.00N/AN/AN/ABCTXBriacell Therap 3.00Buy$32.003,908.52% UpsideBGXXBright Green 0.00N/AN/AN/ACSCICOSCIENS Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ARAV, BCTX, CSCI, and BGXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BCTXBriacell TherapHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVARAVIVE$9.14M0.32N/AN/AN/A∞BCTXBriacell TherapN/AN/AN/AN/A($2.20) per shareN/ABGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/ACSCICOSCIENS Biopharma$9.59M1.42N/AN/A$3.49 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVARAVIVE-$76.32MN/A0.00∞N/AN/AN/AN/AN/ABCTXBriacell Therap-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/ABGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/ACSCICOSCIENS Biopharma-$15.31M-$5.80N/A∞N/A-194.50%-101.01%-43.90%8/12/2025 (Estimated)Latest ARAV, BCTX, CSCI, and BGXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/A5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVARAVIVEN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/ABGXXBright GreenN/AN/AN/AN/AN/ACSCICOSCIENS BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVARAVIVEN/AN/AN/ABCTXBriacell TherapN/A3.413.41BGXXBright GreenN/A0.010.01CSCICOSCIENS BiopharmaN/A2.882.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVARAVIVE35.80%BCTXBriacell Therap15.42%BGXXBright Green7.83%CSCICOSCIENS Biopharma0.73%Insider OwnershipCompanyInsider OwnershipARAVARAVIVE60.40%BCTXBriacell Therap5.73%BGXXBright Green62.55%CSCICOSCIENS Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVARAVIVE2073.56 million29.13 millionNo DataBCTXBriacell Therap86.78 million6.39 millionNo DataBGXXBright Green2191.17 million71.59 millionNo DataCSCICOSCIENS Biopharma203.15 million3.14 millionN/AARAV, BCTX, CSCI, and BGXX HeadlinesRecent News About These CompaniesCOSCIENS Biopharma Inc. Announces Voting Results from 2025 Annual General and Special Meeting of ShareholdersJune 30, 2025 | quiverquant.comQCOSCIENS Biopharma Announces Results of Virtual 2025 Meeting of ShareholdersJune 30, 2025 | globenewswire.comCSCI COSCIENS Biopharma Inc.June 1, 2025 | seekingalpha.comCOSCIENS Biopharma Inc. Reconstitutes Board for Benefit of ShareholdersMay 30, 2025 | financialpost.comFCOSCIENS Biopharma Inc. Reconstitutes Board for Benefit of ShareholdersMay 30, 2025 | finance.yahoo.comCOSCIENS Biopharma Inc. Announces Reconstitution of Board Following Resolution Agreement with GoodwoodMay 30, 2025 | quiverquant.comQCosciens Biopharma announces receipt of Goodwood intended director nominationsMay 27, 2025 | finance.yahoo.comCOSCIENS Biopharma Receives Director Nominations Ahead of Shareholder MeetingMay 27, 2025 | tipranks.comCOSCIENS Biopharma Receives Director Nominations from GoodwoodMay 26, 2025 | tipranks.comCOSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for ...May 26, 2025 | gurufocus.comCOSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of ShareholdersMay 26, 2025 | financialpost.comFCOSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for ...May 26, 2025 | gurufocus.comCOSCIENS Biopharma Inc. Acknowledges Director Nominations from Goodwood Fund Ahead of Annual Shareholder MeetingMay 26, 2025 | quiverquant.comQCOSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of ShareholdersMay 26, 2025 | globenewswire.comGoodwood to Nominate New Directors for COSCIENS Biopharma Inc.May 23, 2025 | finance.yahoo.comCOSCIENS Biopharma reports key corporate updatesMay 21, 2025 | uk.investing.comCOSCIENS Biopharma Completes Merger with Ceapro and Restructures GovernanceMay 20, 2025 | tipranks.comCosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)May 19, 2025 | theglobeandmail.comCosciens Biopharma Inc CSCIMay 15, 2025 | morningstar.comMCOSCIENS Biopharma: Q1 Earnings SnapshotMay 13, 2025 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARAV, BCTX, CSCI, and BGXX Company DescriptionsARAVIVE NASDAQ:ARAV$0.04 0.00 (0.00%) As of 07/18/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Briacell Therap NASDAQ:BCTX$0.80 -0.03 (-3.98%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.81 +0.02 (+1.97%) As of 07/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Bright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.COSCIENS Biopharma NASDAQ:CSCI$4.33 +0.23 (+5.61%) Closing price 07/18/2025 03:56 PM EasternExtended Trading$4.28 -0.05 (-1.27%) As of 07/18/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
